Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers
Óskar Þór Jóhannsson(National University Hospital of Iceland), Håkan Olsson(Nokia (Finland)), Åke Borg(Lund University), Henrik Møller(Danish Institute for Quality and Accreditation in Healthcare), Ulf Kristoffersson, Niklas Loman(Lund University)
Cited by 122
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k